Flash Finance

Senores Pharmaceuticals LimitedSENORESCorporate

Pharmaceuticals - Indian - Formulations Latest results: Jun 2026 11 quarters of data
Consolidated Standalone
₹1,318.40
MCap ₹6,072 Cr · P/E 46.3
Senores Pharmaceuticals Limited — Stock analysis & AI research Senores Pharmaceuticals Limited — Multibagger AI analysis Senores Pharmaceuticals Limited — Seasonality — best & worst months Senores Pharmaceuticals Limited — Technical indicators & charts Senores Pharmaceuticals Limited — Technical setup — score, trend, support & resistance Senores Pharmaceuticals Limited — Live exchange announcements
📋 High Operating Margin Stocks📋 High Profit Growth Stocks📋 Stocks With Strong Quarterly Results 📈 Bollinger Squeeze Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹180 Cr
Sales · Jun 2026
+30.6% YoY
₹54 Cr
Operating Profit · Jun 2026
+57.4% YoY
29.8%
OPM % · Jun 2026
+20.2% YoY
₹30 Cr
Net Profit · Jun 2026
+43.8% YoY
₹6.61
EPS · Jun 2026
+43.7% YoY

📝 Senores Pharmaceuticals Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Senores Pharmaceuticals Limited reported revenue of ₹180 crore for the quarter ended June 2026 (Q1 FY27), up 30.6% from ₹138 crore in the same quarter last year, and up 3.0% sequentially over the March 2026 quarter.

Net profit rose 43.8% year-on-year to ₹30 crore, from ₹21 crore. Earnings per share (EPS) came in at ₹6.61.

Operating profit stood at ₹54 crore — an operating margin (OPM) of 29.8%, compared with 24.8% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Senores Pharmaceuticals Limited posted revenue of ₹649 crore, a growth of 63.0% over FY25, with a net profit of ₹122 crore (up 108.7% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹692 crore with a net profit of ₹131 crore.

Valuation snapshot

At the current price of ₹1,318.40, SENORES has a market capitalisation of ₹6,072 crore and a trailing P/E of about 46.3.

Within the Pharmaceuticals - Indian - Formulations industry, it is the 5th-largest of the 20 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 45.82%, foreign institutional investors (FIIs) 6.01%, domestic institutional investors (DIIs) 10.84%, public shareholders 37.33% of Senores Pharmaceuticals Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹6,072 Cr
Current Price ?
₹1,318.4
P/E ?
46.30above ind
Industry P/E ?
21.30
P/B ?
6.50
P/S ?
8.78
P/FCF ?
-29.91
Enterprise Value ?
₹6,414 Cr
EV/EBITDA ?
31.40
PEG ?
0.33
Earnings Yield ?
2.3%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹692 Cr
OPM ?
29.5%
Profit after tax (TTM) ?
₹131 Cr
EPS (TTM) ?
₹28.48
ROCE ?
15.0%
ROE ?
14.0%
ROA ?
8.2%
Growth
Sales — latest qtr ?
₹180 Cr
PAT — latest qtr ?
₹30 Cr
YoY qtr sales growth ?
30.6%
YoY qtr profit growth ?
43.8%
Sales growth (3y) ?
162%
Sales growth (5y) ?
N/A
Profit growth (3y) ?
139%
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹342 Cr
Debt to Equity ?
0.37
Interest Coverage ?
3.2
Current Ratio ?
N/A
Ownership
Promoter holding ?
45.82%
Change in promoter holding ?
0.04%
Pledged percentage ?
N/A
Market
Return 3 months ?
-6.2%
Return 6 months ?
47.5%

🗓️ Quarterly results (11 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 7910280101103114138162175175180 +30.6% +3.0%
Operating Profit 1522212326193450544754 +57.4% +14.4%
Other Income 1202512354143 -16.4% -79.9%
Interest 235565565257 +42.3% -71.4%
Depreciation 3444456883110 +65.9% -68.2%
Profit Before Tax 10181316202126414515939 +49.0% -75.2%
Net Profit 714111316182130343730 +43.8% -17.7%
EPS 2.375.233.233.865.043.814.606.547.296.866.61 +43.7% -3.6%
OPM % 19.0% 21.6% 26.2% 22.8% 24.9% 17.0% 24.8% 30.6% 30.9% 26.9% 29.8% +20.2% +10.8%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹398 Cr ₹649 Cr ₹692 Cr +63.0%
Operating Profit ₹89 Cr ₹185 Cr ₹204 Cr +107.2%
OPM % 22.38% 28.44% 29.54% +27.1%
NPM % 14.66% 18.77% 18.97% +28.0%
Other Income ₹19 Cr ₹27 Cr ₹26 Cr +40.3%
Depreciation ₹17 Cr ₹53 Cr ₹57 Cr +205.2%
Interest ₹21 Cr ₹42 Cr ₹44 Cr +93.8%
EBIT ₹72 Cr ₹131 Cr ₹147 Cr +83.4%
PBT ₹70 Cr ₹271 Cr ₹284 Cr +286.0%
Tax ₹7 Cr ₹27 Cr ₹31 Cr +296.5%
Net Profit ₹58 Cr ₹122 Cr ₹131 Cr +108.7%
EPS ₹15.94 ₹25.29 ₹27.30 +58.7%
Material Cost ₹95 Cr ₹189 Cr ₹197 Cr +98.3%
Employee Cost ₹34 Cr ₹82 Cr ₹90 Cr +143.6%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 10314646 +0.0%
Reserves 36174740888 +20.0%
Borrowings 63258315342 +8.6%
Other Liabilities 23160126328 +160.3%
Total Liabilities 1316221,2271,604 +30.7%
Fixed Assets 27235301755 +150.8%
CWIP 349717217 -90.1%
Investments 16004 —
Other Assets 53289754827 +9.7%
Total Assets 1316221,2271,604 +30.7%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity -1-26-4662 +234.8%
Cash from Investing Activity -48-54-429-121 +71.8%
Cash from Financing Activity 4687573-1 -100.2%
Net Cash Flow -3898-60 -161.2%
Free Cash Flow -48-78-203-203 +0.0%
CFO/OP 3%-56%-41%45% +209.8%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 228191114187 +64.0%
Inventory Days 89184232130 -44.0%
Days Payable 388556275340 +23.6%
Cash Conversion Cycle -71-18270-24 -134.3%
Working Capital Days -7-1688132 +50.0%
ROCE % 18%12%11%15% +36.4%

👥 Shareholding (latest 6 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026 % Chg
Promoters 45.78%45.80%45.81%45.82%45.82%45.82% +0.0%
FIIs 3.66%4.28%3.35%3.64%6.62%6.01% -9.2%
DIIs 9.51%8.62%9.32%9.62%9.77%10.84% +11.0%
Public 41.03%41.30%41.54%40.92%37.79%37.33% -1.2%
No. of Shareholders 36,38934,91734,40134,12636,49842,642 +16.8%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Formulations · 20 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SHILPAMED Shilpa Medicare ₹1,032.00 20,184 67.5 1,683 297 28.4% 17.7% 47.7% 454.9% 44.9% 115.2%
2 MARKSANS Marksans Pharma ₹332.50 15,068 29.1 3,171 521 22.5% 16.4% 12.5% 9.7% 35.6% 174.8%
3 BLISSGVS Bliss GVS ₹680.50 7,236 52.9 1,005 142 19.7% 14.1% 14.4% 48.7% 37.6% 15.8%
4 JSLL Jeena Sikho ₹507.55 6,309 26.7 852 236 42.6% 27.7% 17.1% 85.5% 28.8% 28.0%
5 SENORES Senores Pharmaceuticals ₹1,327.50 6,114 46.6 692 131 29.5% 19.0% 63.0% 108.7% 30.6% 43.8%
6 WINDLAS Windlas Biotech ₹1,129.50 2,331 35.7 942 66 11.1% 7.1% 18.9% 9.0% 18.1% -0.1%
7 VENUSREM Venus Remedies ₹1,651.10 2,210 19.0 811 117 20.4% 14.4% 17.9% 127.9% 35.6% 139.3%
8 SYNCOMF Syncom Formulations ₹23.44 2,203 1.3 12,547 1,729 15.2% 13.8% 2566.9% 3386.8% 7.4% 57.7%
9 HESTERBIO Hester Biosciences ₹2,187.90 1,861 13.6 318 137 30.8% 43.0% 4.7% 101.2% -8.4% 460.8%
10 AMRUTANJAN Amrutanjan Health ₹489.00 1,413 26.2 512 54 14.4% 10.5% 11.0% 1.3% 9.5% -45.4%
11 LINCOLN Lincoln Pharmaceuticals ₹601.50 1,205 12.5 694 97 14.6% 14.0% 7.6% 7.2% 15.1% 30.9%
12 BAFNAPH Bafna Pharmaceuticals ₹301.45 713 91.6 143 8 8.2% 5.5% 3.3% 166.8% -23.2% -97.8%
13 KILITCH Kilitch Drugs ₹198.00 692 16.1 237 29 15.3% 12.3% 18.7% 20.1% 4.0% -13.0%
14 MEDICAMEQ Medicamen Biotech ₹323.80 439 1.3 9,516 381 10.1% 4.0% 5751.8% 3308.0% 11.3% 15.3%
15 QUESTLAB Quest Laboratories ₹137.50 225 13.7 150 16 12.7% 11.0% 25.8% 34.9% -30.2% 47.9%
16 JFLLIFE Jfl Life ₹51.05 168 24.7 131 7 9.1% 5.2% 60.2% 53.1% -4.2% 48.5%
17 ZENITHDRUG Zenith ₹78.45 135 41.7 171 4 7.0% 2.3% — — 40.9% 100.0%
18 ALPA Alpa Laboratories ₹62.32 131 29.6 111 4 1.7% 4.0% -5.9% -22.5% 25.2% -91.7%
19 MEDIORG Medicamen ₹101.45 119 — 22 -3 -12.9% -14.0% — — -77.5% -383.0%
20 BIOFILCHEM Biofil Chemicals ₹33.13 54 110.4 34 0 2.3% 1.4% -15.0% 405.5% 92.1% -95.5%
❓ Frequently asked questions
What was Senores Pharmaceuticals Limited's revenue in Q1 FY27?
Senores Pharmaceuticals Limited reported revenue of ₹180 crore for the quarter ended June 2026 (Q1 FY27), up 30.6% from ₹138 crore in the same quarter last year, and up 3.0% sequentially over the March 2026 quarter.
What was Senores Pharmaceuticals Limited's net profit in Q1 FY27?
Net profit rose 43.8% year-on-year to ₹30 crore, from ₹21 crore. Earnings per share (EPS) came in at ₹6.61.
What is SENORES's market capitalisation and P/E ratio?
At the current price of ₹1,318.40, SENORES has a market capitalisation of ₹6,072 crore and a trailing P/E of about 46.3.
Who owns Senores Pharmaceuticals Limited? (shareholding pattern)
As of Sep 2026, promoters held 45.82%, foreign institutional investors (FIIs) 6.01%, domestic institutional investors (DIIs) 10.84%, public shareholders 37.33% of Senores Pharmaceuticals Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI